Acambis at neutral by Merrill

Merrill Lynch analyst Erica Whittaker rated Acambis plc at neutral on news that the U.S. government is no longer considering the company's proposal for the MVA "safe" smallpox vaccine contract award. The rejection is based on a "technical" reason that needs to be clarified, according to the analyst. The news is not expected to impact the ongoing negotiations with the government on the multi-year "warm base" ACAM2000 smallpox vaccine stockpile maintenance contract. Shares of the Cambridge, England-based pharmaceutical company were up 13.50p, or 14.25%, at 108.25p. (London: ACM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.